by Illumina. “The problem was we never had ... For more than a decade, researchers had tried without success to move Sanger sequencing to a chip, but this technique was not scalable, he says.

Core Illumina sequencing service and other revenues totaled $150 million, up 6% year over year. Sequencing consumable revenues amounted to $741 million, up 7% year over year, primarily due to ...

Illumina, Inc. (NASDAQ:ILMN) was removed from the index. Year to date, the stock has increased around 8%, underperforming iShares Core S&P Mid-Cap ETF (NYSE:IJH). The provider of DNA sequencing ...